ATE324451T1 - Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung - Google Patents

Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung

Info

Publication number
ATE324451T1
ATE324451T1 AT98202021T AT98202021T ATE324451T1 AT E324451 T1 ATE324451 T1 AT E324451T1 AT 98202021 T AT98202021 T AT 98202021T AT 98202021 T AT98202021 T AT 98202021T AT E324451 T1 ATE324451 T1 AT E324451T1
Authority
AT
Austria
Prior art keywords
surface antigen
immunogen
capacity
increased
vaccine preparation
Prior art date
Application number
AT98202021T
Other languages
English (en)
Inventor
Gonzalez Verena L Muzio
Ave Y Nuevo Vedado Entre
Arias Eduardo Penton
Escobar Giuvel Fontirrochi
Galvez Marcelo Nazabal
Griego Marta De Jesus Gonzalez
Asuncion Esquina
Iznaga Alejandro Beldarrain
Gonzalez Guillermo Juli Padron
Albajes Victoria Ramirez
Pena Arnaldo Garcia
Cruz Carlos Enrique Ruiz
Lopez Gladys Mabel Izquierdo
Y Josefina Gertudis
Martinez Luis Saturnin Herrera
Cano Carlos Antonio Duarte
Cubay San Ignacio Apto
Suarez Lilia Luisa Perez
Suarez Jose Garcia
La Riva De La Riva Gustavo De
Strampes Y Goicuria D
Avila Ramon Alexis Santiago
Zorrilla Filiberto Rosend Ayon
Meireles Rolando Paez
Fierro Alberto Agraz
Betancourt Raul Enrique Diaz
Maya Yair Quinones
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE324451T1 publication Critical patent/ATE324451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT98202021T 1990-10-08 1991-10-07 Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung ATE324451T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU90155A CU22290A1 (es) 1990-10-08 1990-10-08 Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal

Publications (1)

Publication Number Publication Date
ATE324451T1 true ATE324451T1 (de) 2006-05-15

Family

ID=5459466

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91202615T ATE175445T1 (de) 1990-10-08 1991-10-07 Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen
AT98202021T ATE324451T1 (de) 1990-10-08 1991-10-07 Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT91202615T ATE175445T1 (de) 1990-10-08 1991-10-07 Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen

Country Status (9)

Country Link
EP (2) EP0480525B1 (de)
JP (2) JP3189212B2 (de)
AT (2) ATE175445T1 (de)
AU (1) AU649482B2 (de)
CU (1) CU22290A1 (de)
DE (2) DE69133525T8 (de)
DK (2) DK0480525T3 (de)
ES (2) ES2264183T3 (de)
GR (1) GR3029582T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU95109861A (ru) * 1994-06-09 1997-06-10 Сентро Де Инженьериа Генетика И Биотекнологиа (Cu) Рекомбинантный фрагмент антитела, применение scfv, применение фрагмента антитела или пептида, способ получения scfv
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1403274A1 (de) * 2002-09-30 2004-03-31 Meristem Therapeutics Verfahren zur Reinigung von rekombinanten Proteinen aus komplexen Medien sowie die auf diese Weise erhaltenen gereinigten Proteine
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
JP4936272B2 (ja) * 2006-02-13 2012-05-23 独立行政法人科学技術振興機構 バイオナノカプセルの効率的な精製法
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
JP6981992B2 (ja) 2016-03-31 2021-12-17 セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア Ｂ型肝炎ウイルスの表面及び核内抗原を含む医薬組成物
KR102630293B1 (ko) * 2021-06-21 2024-01-29 선지호 박스 포장 테이프 절단용 칼날유닛과 이를 이용한 박스 포장 테이프 절단장치.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
KR900008591B1 (ko) * 1988-05-13 1990-11-26 동아제약 주식회사 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법

Also Published As

Publication number Publication date
JPH0576370A (ja) 1993-03-30
GR3029582T3 (en) 1999-06-30
EP0864649B1 (de) 2006-04-26
DE69133525T2 (de) 2006-11-23
EP0864649A2 (de) 1998-09-16
CU22290A1 (es) 1995-01-31
ATE175445T1 (de) 1999-01-15
DK0864649T3 (da) 2006-08-28
DE69133525T8 (de) 2007-03-08
DE69133525D1 (de) 2006-06-01
AU8557491A (en) 1992-04-30
DE69130724D1 (de) 1999-02-18
EP0480525A2 (de) 1992-04-15
JP3242640B2 (ja) 2001-12-25
DE69130724T2 (de) 1999-06-17
EP0480525A3 (en) 1992-09-30
ES2129025T3 (es) 1999-06-01
DK0480525T3 (da) 1999-08-30
EP0480525B1 (de) 1999-01-07
ES2264183T3 (es) 2006-12-16
EP0864649A3 (de) 1998-11-11
JP3189212B2 (ja) 2001-07-16
AU649482B2 (en) 1994-05-26
JP2001231582A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
DE69031556D1 (de) Antigene sowie Verfahren zu deren Herstellung
ATE324451T1 (de) Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung
EP0271302A3 (de) T-Zell-Epitope von Hepatitis-B-Virus-Nukleocapsid-Protein
DE69116781D1 (de) Integriertes Verfahren zur Herstellung von Kohlenoxyd
DE3780514D1 (de) Verfahren zur herstellung von methacryloxy- oder acryloxyorganosilanen oder -organosiliconen.
ATE87003T1 (de) Oligosaccharide, immunogene und impstoffe und verfahren zur herstellung dieser oligosaccharide, immunogene und impstoffe.
ATE259878T1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
DE3575520D1 (de) Rabies-vakzine und verfahren zur herstellung.
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
ATE5592T1 (de) Verfahren zur herstellung von 4'deoxydaunorubicin und 4'-deoxydoxorubicin, sowie 4'-epi-4'-trifluormethyl-sulfonyloxy-ntrifluoracetyldaunorubicin.
PT73021B (en) Process for producing dna sequences of recombinant dna molecules and polipeptides with specificyty on foot mouth disease as viral antigens
ATE143812T1 (de) Verfahren zur herstellung von virusinaktivierten immunglobulinlösungen
ATE61230T1 (de) Verfahren zur herstellung einer keuchhustenimpfstoffkomponente und kombinierter impfstoff,bestehend aus keuchhustenantigen diphterietoxoid und tetanustoxoid.
EP0198299A3 (de) Verfahren zur Herstellung von Hepatitis-B-Oberflächenantigen enthaltenden Partikeln in neuer Form, die hoch immunogen sind
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
DE3870663D1 (de) Verfahren zur herstellung von silizium-carbid-whiskern.
ATE77361T1 (de) Verfahren zur herstellung von hochsiedenden acrylaten bzw. methacrylaten.
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
DE69128547D1 (de) Verfahren zur Herstellung von kondensierten Alkoholen mit einem Alkoxidkatalysator
ATE54604T1 (de) Verfahren zur herstellung von verbundkoerpern mit einem polyurethan-inneren und der so hergestellte verbundkoerper.
ATE64830T1 (de) Verfahren zur herstellung von textilverstaerkung und damit erhaltenes gewebe.
PT85052A (de) Verfahren zur herstellung einer pasteurisierten immunglobulin- praparation
ATE150438T1 (de) Verfahren zur herstellung von 1,1,1,2- tetrafluorethan
DE69119230D1 (de) Schützende antikörper erregende plasmodium falciparum antigene und deren verwendung in impfstoffen
TH3773A (th) วัคซีนป้องกันมาเลเรีย

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0864649

Country of ref document: EP

REN Ceased due to non-payment of the annual fee